Immunotherapy and chemoradiation after bile duct cancer surgery
Part of Cancer clinical trials.
This trial tests whether combining immunotherapy with chemotherapy and radiation after surgery can help prevent bile duct cancer from coming back in people who have a high risk of recurrence.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 70 years old.
- You have had surgery to remove bile duct cancer, and the pathology showed high-risk features (cancer in lymph nodes, nerve invasion, or a positive margin).
- You are well enough to do daily activities (ECOG 0 or 1).
- Your blood counts, liver, and kidney function are within normal ranges.
- You have not had other cancer treatments before surgery, and you haven't had another cancer in the last 5 years (except certain skin cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining chemotherapy with radiation after surgery can help prevent the return of intrahepatic cholangiocarcinoma, a type of bile duct cancer. It is for people whose surgery showed a narrow margin or cancer in nearby lymph nodes.
This trial tests a combination of chemotherapy, immunotherapy (adebrelimab), and a targeted therapy (apatinib) before and after surgery for bile duct cancer that can be removed and has a high risk of coming back. It aims to see if this approach can lower the chance of recurrence.
This trial tests a combination of chemotherapy directly into the liver artery, an immunotherapy drug, and a targeted therapy pill before surgery for a type of bile duct cancer that has a high chance of coming back. The goal is to see if this approach can improve outcomes for patients whose cancer is still removable but has certain high-risk features.
This trial tests a combination of immunotherapy (tislelizumab) and chemotherapy (gemcitabine, cisplatin, S-1) given before surgery for patients with bile duct cancer that is high-risk for return or has come back within 6 months after a prior surgery. The goal is to see if this treatment can improve outcomes.
This trial tests a combination of an immunotherapy (adebrelimab), a targeted therapy (apatinib), and two chemotherapy drugs (gemcitabine and cisplatin) given before surgery for biliary tract cancers that are removable but at high risk of coming back. The goal is to see if this approach helps shrink the tumor and improve outcomes after surgery.
This trial tests a combination of chemotherapy drugs (gemcitabine, cisplatin, nab-paclitaxel) with an immunotherapy (rilvegostomig) before and after surgery for intrahepatic cholangiocarcinoma that can be completely removed. It aims to see if this approach improves outcomes.
Hear when a new Lymph Node Metastasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.